特应性皮炎是最常见的湿疹类型，是一种慢性炎症性疾病，会导致皮肤过度干燥、瘙痒并伴有疼痛。中度至重度特应性皮炎患者会出现慢性症状，不可预测的发作会加剧症状，可能带来疼痛并扰乱日常生活。这些患者中几乎有一半报告出现严重瘙痒，导致反复抓挠，这会导致皮肤增厚 ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

周五，H.C. Wainwright维持对Astria Therapeutics (NASDAQ:ATXS)的买入评级，目标价格坚持在16.00美元。该公司的关注点集中在本周早些时候关于一种竞争性特应性皮炎(AD)治疗方法的最新进展上。安进公司宣布了其OX40抗体rocatinlimab在HORIZON试验中的初步第三期结果。 研究报告显示，rocatinlimab的表现优于安慰剂，达到了所有主要 ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

2024年9月24日，安进公布自免/炎症领域最新临床进展，包括OX40抗体Rocatinlimab治疗特应性皮炎、CD19抗体Uplizna治疗IgG4相关疾病 ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

BMO Capital对Amgen (NASDAQ: AMGN)股票保持积极展望，重申"跑赢大市"评级，目标价维持在362.00美元。 该公司的分析强调了Amgen最近临床试验的喜忧参半结果。Amgen的rocatinlimab在特应性皮炎治疗中的III期HORIZON研究显示，在24周时EASI-75反应率达到32.8%，具有统计学显著性。

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...